Timely obesity care should not depend on where you live
Dr Claudia Coelho, Association for the Study of Obesity
In my specialist weight management clinic at Guy’s and St Thomas’, I often see people who have spent years trying to manage their weight before they get an appointment. By the time we meet, they want to know what treatment is available and when they can start. I thought about those conversations when I gave evidence on behalf of the Association for the Study of Obesity (ASO) to the House of Commons Health and Social Care Committee on 25 February 2026. The experiences people had shared with the Committee were familiar to me from clinic.
A referral needs to lead to treatment
Better treatments are available now, but what I can offer a patient still depends in part on where they live. When specialist teams are stretched, waiting times grow, referral criteria tighten and services sometimes have to pause referrals altogether. Even once someone gets an appointment, local criteria can restrict access to medicines, and bariatric surgery remains underprovided.
More referrals might help show how much need there is. For the person being referred, though, what matters is whether they can start treatment. I’d put some of the funding for referral incentives directly into providing care. A national framework could set out the minimum that integrated care boards (ICBs) should commission, with ring-fenced funding to help them deliver it.
Reaching people with the greatest clinical need
In south-east London, we’ve used primary care records during the tirzepatide rollout to identify people who may be eligible for treatment. Our ICB works with GP federations to do this. It takes careful work. Cardiovascular disease, for example, can be recorded in several ways, so a search using a single code could miss someone.
What I see in this approach is a chance to reach people with severe and complex obesity who might never ask for a referral. Finding more people does put pressure on services, so we need to plan how we’ll treat the people we identify. We also need to understand better who faces the greatest health risks and who is most likely to benefit from each treatment.
What a long-term approach means in clinic
When I first see someone in clinic, I want to understand what was happening in their life when they started to gain weight. Were they working shifts, taking a medicine that can contribute to weight gain, or finding it harder to stay active? Has disordered eating played a part? I also want to know how their weight is affecting their health now, from their mobility and mental health to conditions such as type 2 diabetes. BMI is one part of that assessment. NICE recommends also using waist-to-height ratio in adults with a BMI below 35 to help assess health risks.
After weight loss, the body’s appetite signals can make it harder to maintain that loss. People can regain weight after stopping medication, which is one reason I think about how we’ll support someone over the long term from the outset. Lower prices, oral medicines and different treatment combinations could change how we provide that care. New evidence is particularly worth reviewing when it could change what we do in practice. When someone who cannot access NHS treatment is considering a private prescription, we also talk about how to find a reliable provider.
I understand why the language matters, especially for people who have felt blamed for their weight. Recognising obesity as a complex, treatable condition that can relapse helps explain why people may need ongoing support. Formal recognition as a disease could strengthen the case for long-term funding. We can improve access to care now.
Finding out who gets care and what happens next
I’d like us to be able to answer some basic questions about obesity care in England. Who gets through the door? Who starts treatment? How are they doing a year or more later? In diabetes care, we have a way to collect data across primary and secondary care and compare how services are doing. A national obesity treatment registry could help us do the same. Specialist services would need a common set of measures, the systems to collect them and a requirement to report them.
In our written evidence, ASO calls for medicines to be offered as part of multidisciplinary care, with nutritional, behavioural and psychological support. We also call for action on weight stigma and the social and environmental drivers of obesity. For the people I see in clinic, progress would mean getting to the right service sooner, having a choice of appropriate treatments and knowing where to turn for support over time.